We treated 27 children with idiopathic epilepsy with zonisamide monotherapy over a period of 2 years and observed behaviour disturbances in a prospective study.
INTRODUCTION
Zonisamide is an anticonvulsant for partial seizures and is also effective for generalized seizures. Recently, zonisamide-related psychotic or behavioural problems have been reported 1, 2 , primarily noted in adults with polypharmacy, and many of these patients were physically and/or mentally disturbed. There are a few reports 3 , however, of behaviour disturbances provoked by zonisamide monotherapy in epileptic children who are neither physically nor mentally disturbed. We used zonisamide monotherapy to successfully treat two mentally normal epileptic children when behaviour disturbances developed. The cases presented here suggest a direct correlation between zonisamide and behaviour disturbances, as no other factors were evident.
METHOD
We treated 27 children with idiopathic epilepsy (17 males and 10 females) with zonisamide monotherapy over a period of 2 years and observed behaviour disturbances in a prospective study. All children met the following criteria:
1. Epilepsy onset prior to age 14 years.
2. Absence of seizures for over 1 year.
3. Absence of physical or mental problems.
Normal brain computed tomography (CT) or magnetic resonance imaging (MRI).
Nineteen patients were treated with zonisamide monotherapy from the beginning and eight were treated with other antiepileptics prior to treatment with zonisamide.
RESULTS AND CASE REPORT
Two of 27 children (7.4%) showed behaviour disturbances.
Case 1: Selective mutism etc.
Since the age of 4 years, a 14-year-old girl had experienced partial seizures evolving to secondary generalized seizures of unknown aetiology. Her seizures started with vomiting followed by a loss of consciousness and left arm clonic seizures. There was no family history of such episodes, and physical and neurological examination revealed no abnormalities. Her brain CT scan was normal. Clonazepam was the first therapy administered, not by the authors, and was discontinued probably because unknown adverse effects developed. We administered carbamazepine, which was not effective, then added zonisamide to the regimen at age 6 years. Seizures ceased after the addition of zonisamide, so the carbamazepine dosage was gradually reduced and eventually discontinued at age 7 years.
At a body weight of 20-24 kg, the patient's seizures were well controlled with 150 mg of zonisamide administered daily. Serum levels of zonisamide ranged from 15.9 to 23.8 µg ml −1 (therapeutic range, 10-30 µg ml −1 ). Electro-encephalogram (EEG) at onset (age 4 years) showed right occipital spike and wave activity which disappeared at age 7 years. Selective mutism developed at age 10 years as the patient was unwilling to speak when asked questions by her teachers in school. We also noted that the patient erupted easily into violent behaviour and became irrational and angry despite no observable stimuli. She also demonstrated emotional instability and impaired concentration. She had no insomnia. Her full scale IQ was 105 on the revised Wechsler Intelligence Scale for Children. In addition, she had a low group conformity rating (38%, below 1 SD) and high scores of immature extra-punitive (44%, over 2 SD) and extra-aggression (81%, over 2 SD) as determined by the PictureFrustration Test. Her serum level of zonisamide was 18.4 µg ml −1 .
Although there were frequent family quarrels, we suspected that zonisamide might be responsible for behaviour disturbances and we reduced the dosage. No other medicine was prescribed. The above behaviour disappeared when the zonisamide dosage was decreased to 60 mg. Zonisamide dosage was gradually reduced and discontinued. No other adverse effects or abnormal laboratory data have been noted and the patient is now enjoying her school life with no seizures.
Case 2: Obsessive compulsive disorders (OCD)
A 15-year-old girl began experiencing generalized tonic-clonic seizures at the age of 10 years. During infancy, she twice had simple febrile seizures. No seizures had previously been reported in her family history, and physical and neurological examination revealed no abnormalities. Her brain CT scan was normal. Her seizures relented after administration of 200 mg zonisamide. Serum levels of zonisamide ranged from 25.7 to 30.4 µg ml −1 and her body weight was 40 kg. EEG at onset showed diffuse spikes, and spike and wave which disappeared at age 11 years. Beginning at age 13 years, the patient felt compelled to wash her hands repeatedly and was unwilling to touch a water faucet with her palms. In addition, she would not use towels on tables and in the kitchen; however, she would use hanging towels that her mother also used. She had no insomnia. Her serum level of zonisamide was 16.4 µg ml −1 . OCD associated with zonisamide was considered. Her Yale Brown Obsessive Compulsive Scale score was 19 (obsession subscale, 10; compulsion subscale, 9). Zonisamide was withdrawn, which reduced her OCD behaviour. No other medication, such as antidepressants, was administered. Her OCD symptoms were nearly under control when zonisamide dosage was decreased to 60 mg. She has been experiencing primary nocturnal enuresis, but this is not associated with seizures, zonisamide, or OCD. No other adverse effects or abnormal laboratory data have been noted.
DISCUSSION
The prevalence of epileptic psychosis or behaviour disturbances is reported to be 2.4 ∼ 4.5% 4, 5 . However, in the cases presented here, it appears that the behaviour disturbances were associated with zonisamide and that zonisamide may be a causative factor. Our conclusion is based on the following: (1) the patients had no previous psychotic or mental problems; (2) the behaviour disturbances appeared after zonisamide administration, albeit 3 or 4 years later, and were resolved by decreasing the zonisamide dosage; and (3) no other anticonvulsants or significant factors were present. The appearance of behaviour disturbances at ages 10 and 13 years suggests that puberty might be involved. The improvement of the behaviour might have been the result of the relief felt as medication was decreased. Although these facts may reduce the likelihood of a causal relation between zonisamide and behaviour disturbances, the possibility of chronic adverse effects still remains.
In the present study we observed behaviour disturbances in only two cases (7.4%). Miyamoto 2 reported that 14 of 74 (19%) adult patients had psychotic episodes while undergoing polytherapy including zonisamide. It appears that the extent of behaviour disturbances, including psychotic problems, depends on the severity of the epilepsy and the presence of concomitant anticonvulsants. Miyamoto 2 also reported males having more psychotic episodes than females, although in the present study both cases involved females.
Mimaki 6 reported that the relationship between serum levels of zonisamide, clinical response, and adverse effects appears to be weak. Mimaki 7 also demonstrated that the zonisamide dose-serum level correlation is linear up to a dose of 10 mg kg −1 in children. This indicates that the relationship between dose, clinical response, and adverse effects also appears to be weak in the dosage usually prescribed. However, Kochak 8 reported that the therapeutic response is directly related to the serum concentration of zonisamide. The two cases described here do not support the studies by Mimaki 6, 7 or Kochak 8 , since the behaviour disturbances appeared with no connection to dosage and were relieved by decreasing the dosage.
In our Case 1, selective mutism and violence were observed with zonisamide administration. Kimura 3 reported zonisamide-induced behaviour disorders similar to this, which also disappeared when the zonisamide was discontinued. Since zonisamide is a sulfonamide derivative, its toxicity in the CNS may be similar to that of sulfonamide 1 .
In Case 2, OCD was seen with zonisamide. Koopowitz 9 showed that carbamazepine, which is structurally similar to zonisamide, was therapeutic for OCD. This is contrary to our observations. Taira 10 reported two cases of resting and postural hand tremor after the administration of zonisamide, which raised the possibility of zonisamide affecting the dopaminergic system. Zonisamide is also thought to influence monoamine metabolism.
In both cases, behaviour disturbances appeared 3-4 years after successful treatment. A seizure-free period is often observed before patients develop psychotic symptoms 11 , although the reason for this delay is unknown. Events such as puberty or other psychological factors merit investigation as contributory factors in this phenomenon.
While zonisamide improved the epilepsy in the two cases presented here, both patients showed behaviour disturbances, which were relieved by decreasing the zonisamide dosage without seizure relapse, at 3-4 years into the treatment. In some cases, low-dose zonisamide therapy may be indicated. In conclusion, zonisamide still appears to be a useful anticonvulsant for epileptic seizures, but physicians should be wary of its adverse behavioural side effects.
